2C-C-NBOMe is derived from the psychedelic phenethylamine 2C-C by substitution on the amine with a 2-methoxybenzyl group. 2C-C-NBOMe is a clumpy white powder with a notably bitter and metallic taste. 2C-C-NBOMe has been found on blotter mimics sold as LSD.[citation needed]
Dosage
Blotter paper containing 2C-C-NBOMe
Anecdotal reports from human users suggest 2C-C-NBOMe to be an active hallucinogen at a dose of as little as 200-500 μg insufflated, making it only slightly less potent than LSD.[3] NBOMe-substituted compounds have a diminished absorption rate passing through mucus membranes, but generally remain inactive when taken orally. Buccal, sublingual or insufflated routes of administration are all viable options. Absorption rate buccally and sublingually can be increased when complexed with HPBCD complexing sugar, however the most efficient is nasal administration, which shortens the duration while increasing intensity, but has been attributed to several overdoses due to improper dosing.[citation needed]
Legal Status
United States
The NBOMe series of compounds are unscheduled in the United States. It is possible that some of them would be considered analogs (of scheduled phenethylamines such as 2C-B or mescaline), in which case, sales for human consumption or possession with the intent to ingest could be prosecuted under the Federal Analogue Act.
One technical note about 2C-X-NBOMe legal status: The primary (easiest) synthetic route for producing 25I-, 25C-, and 25B-NBOMe uses the related controlled substance (2C-I, 2C-C, and 2C-B, respectively) as the precursor chemical. It is likely that NBOMe-compounds sourced from lower-end sources might contain tiny, detectable amounts of a controlled substance. Depending on amount and legal venue, that trace amount could affect the legality of the whole batch.
United Kingdom
N-benzylated phenethylamines such as 2C-C-NBOMe were initially unaffected by the legal status of phenethylamine-class drugs.[4] The British government issued a temporary class drug order on a list of emerging recreational drugs, including 2C-C-NBOMe, on 4 June 2013. The order, which took effect on 10 June 2013 and will last for up to twelve months, prohibits the production, import and sale of “the NBOMe and Benzofury groups of substances”.[5]
New Zealand
2C-C-NBOMe was sold as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and was therefore a Class C controlled drug analogue.[6]
Russia
Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.[7][8]
Israel
The NBOMe series of psychoactives became controlled in Israel in May, 2013.[9][10]
^Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1007/s00259-010-1686-8, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1007/s00259-010-1686-8 instead.
(what is this?) (verify)
